Sign up Australia
Proactive Investors - Run By Investors For Investors

Progen Pharmaceuticals receives second IND application approval in Asia for liver cancer drug

Progen Pharmaceuticals receives second IND application approval in Asia for liver cancer drug

Progen Pharmaceuticals (ASX: PGL) licensee Medigen Biotechnology Corporation can now move to site selection and patient enrolment for a PATRON Phase III study of its liver cancer drug, PI-88, in Korea following approval from the Korea Food and Drug Administration of its Investigative New Drug application.

This is the second Investigative New Drug application approval obtained by Medigen Biotechnology, following the approval granted by the Taiwan Food Administration in April.

The number of patients with hepatocellular carcinoma, the most common form of liver cancer, registered in South Korea is the third highest in Asia, behind China and Japan.

This latest approval means Medigen Biotechnology can now open sites and begin patient enrolment under its PATRON Phase III study of PI-88.

The Phase III, randomised, placebo-controlled, multinational trial will enrol about 500 subjects globally, with the majority of patients enrolled from Asia. The study is expected to be conducted in Taiwan, South Korea, China, Hong Kong and some countries in Europe with high hepatocellular carcinoma prevalence.

It is designed to confirm the efficacy and safety of PI-88 in the adjuvant treatment of hepatocellular carcinoma after surgical resection. The primary endpoint of the study is disease-free survival.

Register here to be notified of future TDL Company articles
View full TDL profile

TBG Diagnostics Timeline

December 07 2015

Related Articles

“Our strategy of investing in future capacity will ensure our ability to provide quality service for this high level of customer need as our partners’ programmes progress,” said chief executive John Burt.
picture of drug research
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.
A graphic of a tumour growing in the body
July 07 2016
Nanobiotix is a late clinical-stage nanomedicine company researching novel approaches to enhance radiotherapy for the local treatment of cancer.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.